Please provide your email address to receive an email when new articles are posted on . New research suggests that use of depot medroxyprogesterone acetate may be associated with an increased risk for ...

September 16, 2009 (Denver, Colorado) — Long-term use of the contraceptive depot medroxyprogesterone acetate (DMPA) has been associated with impaired bone-mineral acquisition in adolescents and ...

Nearly half of women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, will experience high bone mineral density (BMD) loss in the hip or lower spine within two ...

From Case Western Reserve University School of Medicine and Cleveland Clinic, investigators report that depot medroxyprogesterone acetate use was associated with a higher relative risk of meningioma ...

To compare longitudinal changes in weight, body fat, and ratio of central to peripheral fat mass among first-time depot-medroxyprogesterone acetate (DMPA) users to women using no hormonal ...

Researchers at the University of Texas Medical Branch at Galveston have identified women who are likely to gain weight while using depot medroxyprogesterone acetate, more commonly known as ...

The injectable contraceptive depot-medroxyprogesterone acetate (DMPA) appears to increase a woman’s risk of acquiring the sexually transmitted infections chlamydia and gonorrhea by approximately three ...

The FDA approved a label change for the birth control shot depot medroxyprogesterone acetate (Depo-Provera), which now warns about the risk of meningioma, according to a letter posted on the agency ...

New research suggests that use of depot medroxyprogesterone acetate may be associated with an increased risk for fracture in women, particularly in those with longer treatment duration and multiple ...